info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Chronic obstructive pulmonary disease (COPD) Market Research Report Information By CPOD Type (Emphysema, Chronic Bronchitis), By Treatment Type (Drugs, Anti-Inflammatory Drugs, Surgery, Oxygen Therapy), By End Users (Hospitals & Clinics, Homecare Settings, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032


ID: MRFR/Pharma/1081-HCR | 90 Pages | Author: Rahul Gotadki| November 2024

Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation 
Chronic obstructive pulmonary disease (COPD) Type Outlook (USD Billion, 2018-2030)




  • Emphysema




  • Chronic Bronchitis




Chronic obstructive pulmonary disease (COPD) Treatment Outlook (USD Billion, 2018-2030)




  • Drugs




    • Bronchodilator Monotherapy




      • Short-Acting Beta2-Agonists (SABAs)




      • Long-Acting Beta2-Agonists (LABAs)






    • Anti-Inflammatory Drugs




      • Oral And Inhaled Corticosteroids




      • Anti-Leukotrienes








  • Surgery




    • Lung Volume Reduction Surgery (LVRS)




    • Lung Transplant




    • Bullectomy




    • Others






  • Oxygen Therapy




Chronic obstructive pulmonary disease (COPD) End User Outlook (USD Billion, 2018-2030)




  • Hospitals & Clinics




  • Homecare Settings




  • Others




Chronic obstructive pulmonary disease (COPD) Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)




    • North America Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • North America Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • North America Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • US Outlook (USD Billion, 2018-2030)




    • US Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • US Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • US Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Canada Outlook (USD Billion, 2018-2030)




    • Canada Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Canada Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Canada Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others








  • Europe Outlook (USD Billion, 2018-2030)




    • Europe Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Europe Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Europe Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Germany Outlook (USD Billion, 2018-2030)




    • Germany Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Germany Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Germany Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • France Outlook (USD Billion, 2018-2030)




    • France Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • France Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • France Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • UK Outlook (USD Billion, 2018-2030)




    • UK Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • UK Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • UK Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Italy Outlook (USD Billion, 2018-2030)




    • Italy North America Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Italy Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)




          • Anti-Inflammatory Drugs




            • Oral And Inhaled Corticosteroids




            • Anti-Leukotrienes










      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Italy Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Spain Outlook (USD Billion, 2018-2030)




    • Spain Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Spain Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)




          •  






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Spain Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2030)




    • Rest Of Europe Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Rest of Europe Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)


            Anti-Inflammatory Drugs




            • Oral And Inhaled Corticosteroids




            • Anti-Leukotrienes










      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Rest of Europe Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • China Outlook (USD Billion, 2018-2030)




    • China Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • China Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • China Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Japan Outlook (USD Billion, 2018-2030)




    • Japan Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Japan Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Japan Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • India Outlook (USD Billion, 2018-2030)




    • India Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • India Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • India Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • South Korea Outlook (USD Billion, 2018-2030)




    • South Korea Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • South Korea Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • South Korea Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Australia Outlook (USD Billion, 2018-2030)




    • Australia Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Australia Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Australia Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)




    • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2030)




    • Rest of the World Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Rest of the World Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Rest of the World Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Middle East Outlook (USD Billion, 2018-2030)




    • Middle East Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Middle East Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Middle East Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Africa Outlook (USD Billion, 2018-2030)




    • Africa Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Africa Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Africa Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others






    • Latin America Outlook (USD Billion, 2018-2030)




    • Latin America Chronic obstructive pulmonary disease (COPD) by Type




      • Emphysema




      • Chronic Bronchitis






    • Latin America Chronic obstructive pulmonary disease (COPD) by Treatment




      • Metal Drugs




        • Bronchodilator Monotherapy




          • Short-Acting Beta2-Agonists (SABAs)




          • Long-Acting Beta2-Agonists (LABAs)






        • Anti-Inflammatory Drugs




          • Oral And Inhaled Corticosteroids




          • Anti-Leukotrienes








      • Surgery




        • Lung Volume Reduction Surgery (LVRS)




        • Lung Transplant




        • Bullectomy




        • Others






      • Oxygen Therapy






    • Latin America Chronic obstructive pulmonary disease (COPD) by End User




      • Hospitals & Clinics




      • Homecare Settings




      • Others







Research Methodology on Global Chronic Obstructive Pulmonary Disease Market


1. Introduction:


Chronic obstructive pulmonary disease (COPD) refers to a group of chronic lung diseases that have an obstructed airflow from the lungs, including emphysema, chronic bronchitis and/or asthma. It is one of the main causes of morbidity and mortality worldwide and its increasing prevalence has led to a strong interest in research into this condition. This report presents a comprehensive overview of the latest findings in COPD and provides an understanding of the current market trends and emerging treatments. The objective of this research is to provide insights into the COPD market, by analysing the current treatments, and recent developments and assessing their future impact on the market.


2. Literature review:


This research involves a literature review of existing published research studies, reports and literature in the field of COPD, to identify and analyse current trends, developments and treatments available. Relevant databases such as Medline, PubMed, MedlinePlus and ScienceDirect are searched for relevant studies and reports. Relevant articles are carefully screened and those relevant to the research topic are selected based on their level of methodological rigour and relevance to the objectives of the research. Once the relevant articles are identified, the data from each study is collated, appraised and analysed for its relevance and accuracy.


3. Data Collection and Analysis:


The next step in this research is to collect primary data using a qualitative research approach. Semi-structured interviews are conducted with doctors and specialists, key opinion leaders, healthcare professionals and representatives of drug & device manufacturers, to understand their views on the current COPD landscape. In addition to this, patient/consumer surveys are carried out to gain insights into patient/consumer opinions and preferences when it comes to COPD treatments. The primary data collected from these interviews and surveys are analysed using thematic analysis and results are interpreted.


4. Secondary Data Collection and Analysis:


In addition to primary data collection, secondary data is collected from various sources such as WHO, CDC, peer-reviewed journals, and trade reports. This data is analysed to gain an understanding of the current global epidemiology and market trends. Data from the secondary sources are collated, analysed and interpreted.


5. Findings and Recommendations:


The results of both primary and secondary data collection and analysis are presented in a comprehensive report. This report provides an insightful overview of the COPD market, including current treatments, recent developments, trends and future outlook. Furthermore, detailed recommendations are provided to help stakeholders make informed decisions when it comes to developing and marketing new COPD treatments.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE

6.1. Overview

6.2. Emphysema

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Chronic Bronchitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE

7.1. Overview

7.2. Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1. Bronchodilator Monotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1.1. Short-Acting Beta2-Agonists (SABAs)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1.2. Long-Acting Beta2-Agonists (LABAs)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1.3. Anti-Drugs Agent

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2. Anti-Inflammatory Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.1. Oral and Inhaled Corticosteroids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.2. Anti-Leukotrienes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Surgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1. Lung Volume Reduction Surgery (LVRS)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.2. Lung Transplant

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.3. Bullectomy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Oxygen Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Homecare Settings

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Chronic Obstructive Pulmonary Disease (COPD) Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of the Number of Developments in the Global Chronic Obstructive Pulmonary Disease (COPD) Market

10.7. Key Developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Almirall

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Astellas Pharma

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. AstraZeneca

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Boehringer Ingelheim

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Circassia Pharmaceuticals

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. GlaxoSmithKline plc

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Novartis AG

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Pfizer, Inc.

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Teva Pharmaceutical Industries Ltd

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 12 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 15 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET

FIGURE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COPD TYPE, 2020 (%)

FIGURE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY TREATMENT TYPE, 2020 (%)

FIGURE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS

FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 17 ALMIRALL: KEY FINANCIALS

FIGURE 18 ALMIRALL: SEGMENTAL REVENUE

FIGURE 19 ALMIRALL: REGIONAL REVENUE

FIGURE 20 ASTELLAS PHARMA: KEY FINANCIALS

FIGURE 21 ASTELLAS PHARMA: SEGMENTAL REVENUE

FIGURE 22 ASTELLAS PHARMA: REGIONAL REVENUE

FIGURE 23 ASTRAZENECA: KEY FINANCIALS

FIGURE 24 ASTRAZENECA: SEGMENTAL REVENUE

FIGURE 25 ASTRAZENECA: REGIONAL REVENUE

FIGURE 26 BOEHRINGER INGELHEIM: KEY FINANCIALS

FIGURE 27 BOEHRINGER INGELHEIM: SEGMENTAL REVENUE

FIGURE 28 BOEHRINGER INGELHEIM: REGIONAL REVENUE

FIGURE 29 CIRCASSIA PHARMACEUTICALS: KEY FINANCIALS

FIGURE 30 CIRCASSIA PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 31 CIRCASSIA PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 32 GLAXOSMITHKLINE PLC: KEY FINANCIALS

FIGURE 33 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE

FIGURE 34 GLAXOSMITHKLINE PLC: REGIONAL REVENUE

FIGURE 35 NOVARTIS AG: KEY FINANCIALS

FIGURE 36 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 37 NOVARTIS AG: REGIONAL REVENUE

FIGURE 38 PFIZER, INC.: KEY FINANCIALS

FIGURE 39 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 40 PFIZER, INC.: REGIONAL REVENUE

FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.